Xinnate
Private Company
Funding information not available
Overview
Xinnate is a clinical-stage biotech leveraging a platform of innate immune-derived peptides to treat complex skin diseases characterized by dysfunctional healing. Its lead asset, TCP-25 Gel, is a multifunctional therapeutic with a dual mechanism of action that dampens harmful inflammation and directly kills microbes, including antibiotic-resistant strains. The company has initiated a clinical study (STEP) in Epidermolysis Bullosa and is building a robust global IP portfolio. Xinnate represents a novel approach to wound healing by modulating the local immune environment rather than merely addressing symptoms.
Technology Platform
Platform of thrombin-derived C-terminal peptides (TCPs) that modulate the innate immune response. The lead peptide, TCP-25, has a dual mechanism of action: it dampens excessive inflammation by binding PAMPs and blocking CD14 receptor signaling, and it has direct, broad-spectrum antimicrobial activity against bacteria and fungi, including resistant strains.
Opportunities
Risk Factors
Competitive Landscape
In EB, competition includes palliative care, gene/cell therapies in development, and other topical agents. In broader wound care, TCP-25 Gel competes with antimicrobial dressings (silver, PHMB), growth factors, and advanced biomaterials. Its key differentiator is the novel, dual mechanism targeting the root causes of dysfunctional healing.